This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Years of investment in digital, cloud and security strategy has helped Accenture evolve as a trusted and viable consulting services provider. It is currently the world’s top consultancy firm by revenues that increased 5% in 2019 with a contribution of 56% from consulting services.
The Zacks Analyst Blog Highlights Eli Lilly, Accenture, TJX, Novo Nordisk and Salesforce
by Zacks Equity Research
Eli Lilly, Accenture, TJX, Novo Nordisk and Salesforce are included in this Analyst Blog.
Top Stock Reports for Eli Lilly, Accenture & The TJX Companies
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Accenture plc (ACN) and The TJX Companies, Inc. (TJX).
Accenture (ACN) Rises 25% Year to Date: Here's What to Know
by Zacks Equity Research
Accenture (ACN) continues to witness strong demand for application modernization and maintenance, cloud enablement and cybersecurity-as-a-service.
Should You Invest in the iShares U.S. Industrials ETF (IYJ)?
by Zacks Equity Research
Sector ETF report for IYJ
Accenture (ACN) Exceeds Market Returns: Some Facts to Consider
by Zacks Equity Research
Accenture (ACN) closed the most recent trading day at $330.90, moving +0.94% from the previous trading session.
Accenture (ACN) Falls More Steeply Than Broader Market: What Investors Need to Know
by Zacks Equity Research
In the closing of the recent trading day, Accenture (ACN) stood at $315.63, denoting a -1.27% change from the preceding trading day.
Accenture (ACN) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
The latest trading day saw Accenture (ACN) settling at $313.09, representing a -0.13% change from its previous close.
Accenture (ACN) Advances But Underperforms Market: Key Facts
by Zacks Equity Research
Accenture (ACN) reachead $292.70 at the closing of the latest trading day, reflecting a +0.92% change compared to its last close.
CRAI vs. ACN: Which Stock Is the Better Value Option?
by Zacks Equity Research
CRAI vs. ACN: Which Stock Is the Better Value Option?
Accenture (ACN) Rises Yet Lags Behind Market: Some Facts Worth Knowing
by Zacks Equity Research
Accenture (ACN) concluded the recent trading session at $296.09, signifying a +0.39% move from its prior day's close.
Accenture (ACN) Dips More Than Broader Market: What You Should Know
by Zacks Equity Research
Accenture (ACN) reachead $294.94 at the closing of the latest trading day, reflecting a -0.69% change compared to its last close.
CRAI vs. ACN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
CRAI vs. ACN: Which Stock Is the Better Value Option?
5 Stocks to Watch on Recent Dividend Hikes Amid Volatility
by Zacks Equity Research
Investors may keep a tab on stocks like HON, HWM, CNP, ACN and GBCI, which have lately hiked their dividend payments.
Company News for Sep 29, 2023
by Zacks Equity Research
Companies In The News Are: ACN, KMX, JBL, MU.
Accenture (ACN) Surpasses Q4 Earnings Estimates, Rises YoY
by Zacks Equity Research
Accenture's (ACN) improving segmental results helps its earnings and revenues for the fourth quarter to grow year over year.
Here's What Key Metrics Tell Us About Accenture (ACN) Q4 Earnings
by Zacks Equity Research
Although the revenue and EPS for Accenture (ACN) give a sense of how its business performed in the quarter ended August 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Accenture (ACN) Q4 Earnings Top Estimates
by Zacks Equity Research
Accenture (ACN) delivered earnings and revenue surprises of 3.44% and 0.52%, respectively, for the quarter ended August 2023. Do the numbers hold clues to what lies ahead for the stock?
Is ProShares S&P Technology Dividend Aristocrats ETF (TDV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for TDV
The Zacks Analyst Blog Highlights Eli Lilly, Toyota Motor, Accenture, The Walt Disney and CVS Health
by Zacks Equity Research
Eli Lilly, Toyota Motor, Accenture, The Walt Disney and CVS Health are part of the Zacks top Analyst Blog.
4 Crypto Stocks to Watch as Fed Keeps Interest Rates Intact
by Ritujay Ghosh
Bitcoin is poised to rebound in the near term, helping stocks like Robinhood Markets, Inc. (HOOD), Coinbase Global, Inc. (COIN), NVIDIA Corporation (NVDA) and Accenture plc (ACN).
Accenture (ACN) Stock Moves -1.52%: What You Should Know
by Zacks Equity Research
In the latest trading session, Accenture (ACN) closed at $312, marking a -1.52% move from the previous day.
CyberArk (CYBR) & Accenture Team Up to Expand Security Platform
by Zacks Equity Research
CyberArk (CYBR) partners with Accenture to deploy Privileged Access Solution, which will be used by both Accenture and its clients.
Here's What to Expect From Accenture's (ACN) Q4 Results
by Zacks Equity Research
Strong segmental performance mixed with favorable demand and utilization situation are expected to benefit Accenture (ACN) in the fourth quarter of fiscal 2023.
Top Research Reports for Eli Lilly, Toyota Motor, Accenture & Others
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Toyota Motor Corporation (TM) and Accenture plc (ACN).
CRAI or ACN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CRAI vs. ACN: Which Stock Is the Better Value Option?